A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Table 2 CR/CRi rates by subgroup

Subgroup	n/N (%)
AML subtype
Therapy-related AML^#	7/10 (70)
AML arising from prior MDS, MDS/MPN, or MPN (without prior therapy)	4/5 (80)
AML arising from prior MDS, MDS/MPN, or MPN (with prior HMA or chemotherapy)	10/17 (59)
AML-MRC^*	3/4 (75)
Cytogenetics
Poor-risk cytogenetics	11/21 (52)
Non-poor-risk cytogenetics	10/11 (91)
ELN 2017 cytomolecular risk
Intermediate	5/5 (100)
Adverse	16/27 (59)
TP53-mutated	7/11 (64)
MECOM-rearranged	2/4 (50)

MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MRC, myelodysplasia-related changes; HMA, hypomethylating agent; ELN, European LeukemiaNet
^#Includes 4 patients with AML arising from preceding therapy-related myeloid disorder
^*Excluding patients with therapy-related AML or those with preceding myeloid disorder

ISSN: 1756-8722